JP2016027022A - Pharmaceutical composition - Google Patents
Pharmaceutical composition Download PDFInfo
- Publication number
- JP2016027022A JP2016027022A JP2015127296A JP2015127296A JP2016027022A JP 2016027022 A JP2016027022 A JP 2016027022A JP 2015127296 A JP2015127296 A JP 2015127296A JP 2015127296 A JP2015127296 A JP 2015127296A JP 2016027022 A JP2016027022 A JP 2016027022A
- Authority
- JP
- Japan
- Prior art keywords
- hydrochloride
- group
- pharmaceutical composition
- nasal
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 43
- 150000003839 salts Chemical class 0.000 claims abstract description 70
- 206010028735 Nasal congestion Diseases 0.000 claims abstract description 26
- 229960002221 methylephedrine Drugs 0.000 claims abstract description 22
- FMCGSUUBYTWNDP-UHFFFAOYSA-N N-Methylephedrine Natural products CN(C)C(C)C(O)C1=CC=CC=C1 FMCGSUUBYTWNDP-UHFFFAOYSA-N 0.000 claims abstract description 20
- FMCGSUUBYTWNDP-ONGXEEELSA-N (1R,2S)-2-(dimethylamino)-1-phenyl-1-propanol Chemical compound CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 FMCGSUUBYTWNDP-ONGXEEELSA-N 0.000 claims abstract description 19
- 229960001802 phenylephrine Drugs 0.000 claims abstract description 19
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims abstract description 18
- 206010028741 Nasal inflammation Diseases 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 19
- 208000024891 symptom Diseases 0.000 claims description 16
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 12
- 230000001387 anti-histamine Effects 0.000 claims description 12
- 239000000739 antihistaminic agent Substances 0.000 claims description 12
- 206010039083 rhinitis Diseases 0.000 claims description 9
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 229940124579 cold medicine Drugs 0.000 claims description 3
- 201000009240 nasopharyngitis Diseases 0.000 claims description 3
- 206010049153 Allergic sinusitis Diseases 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 5
- -1 methylephedrine salt Chemical class 0.000 description 30
- 206010028748 Nasal obstruction Diseases 0.000 description 23
- NTCYWJCEOILKNG-ROLPUNSJSA-N [(1r,2s)-1-hydroxy-1-phenylpropan-2-yl]-dimethylazanium;chloride Chemical compound Cl.CN(C)[C@@H](C)[C@H](O)C1=CC=CC=C1 NTCYWJCEOILKNG-ROLPUNSJSA-N 0.000 description 23
- 229940073563 dl- methylephedrine hydrochloride Drugs 0.000 description 21
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 description 17
- 229960003733 phenylephrine hydrochloride Drugs 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 239000002775 capsule Substances 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000004698 Polyethylene Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 229960001948 caffeine Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 229940108858 belladonna total alkaloid Drugs 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 230000001629 suppression Effects 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007901 soft capsule Substances 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 229960005042 mequitazine Drugs 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 4
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- DBAKFASWICGISY-DASCVMRKSA-N Dexchlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 DBAKFASWICGISY-DASCVMRKSA-N 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 4
- 229960004708 noscapine Drugs 0.000 description 4
- 229920000573 polyethylene Polymers 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- AKNNEGZIBPJZJG-UHFFFAOYSA-N alpha-noscapine Natural products CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-UHFFFAOYSA-N 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 235000013871 bee wax Nutrition 0.000 description 3
- 239000012166 beeswax Substances 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 229960000428 carbinoxamine Drugs 0.000 description 3
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 3
- 229960003291 chlorphenamine Drugs 0.000 description 3
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 3
- 238000000975 co-precipitation Methods 0.000 description 3
- 229960000325 emedastine Drugs 0.000 description 3
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229960004958 ketotifen Drugs 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 229940073475 lysozyme hydrochloride Drugs 0.000 description 3
- 229960004934 mebhydrolin Drugs 0.000 description 3
- FQQIIPAOSKSOJM-UHFFFAOYSA-N mebhydrolin Chemical compound C1N(C)CCC2=C1C1=CC=CC=C1N2CC1=CC=CC=C1 FQQIIPAOSKSOJM-UHFFFAOYSA-N 0.000 description 3
- 150000004667 medium chain fatty acids Chemical class 0.000 description 3
- 229940051020 methylephedrine hydrochloride Drugs 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- PLPRGLOFPNJOTN-UHFFFAOYSA-N narcotine Natural products COc1ccc2C(OC(=O)c2c1OC)C3Cc4c(CN3C)cc5OCOc5c4OC PLPRGLOFPNJOTN-UHFFFAOYSA-N 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 3
- 206010041232 sneezing Diseases 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- FLNXBVJLPJNOSI-UHFFFAOYSA-N 1-[2-[(4-chlorophenyl)-phenylmethoxy]ethyl]piperidine Chemical compound C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)OCCN1CCCCC1 FLNXBVJLPJNOSI-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 2
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002160 Celluloid Polymers 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 244000000626 Daucus carota Species 0.000 description 2
- 235000002767 Daucus carota Nutrition 0.000 description 2
- 240000006927 Foeniculum vulgare Species 0.000 description 2
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 240000004670 Glycyrrhiza echinata Species 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 2
- 241000721662 Juniperus Species 0.000 description 2
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000000150 Sympathomimetic Substances 0.000 description 2
- ZZHLYYDVIOPZBE-UHFFFAOYSA-N Trimeprazine Chemical compound C1=CC=C2N(CC(CN(C)C)C)C3=CC=CC=C3SC2=C1 ZZHLYYDVIOPZBE-UHFFFAOYSA-N 0.000 description 2
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 2
- 229940008027 aluminum hydroxide / magnesium carbonate Drugs 0.000 description 2
- 230000000954 anitussive effect Effects 0.000 description 2
- 239000003907 antipyretic analgesic agent Substances 0.000 description 2
- 229940124584 antitussives Drugs 0.000 description 2
- 229960004574 azelastine Drugs 0.000 description 2
- YWGDOWXRIALTES-NRFANRHFSA-N bepotastine Chemical compound C1CN(CCCC(=O)O)CCC1O[C@H](C=1N=CC=CC=1)C1=CC=C(Cl)C=C1 YWGDOWXRIALTES-NRFANRHFSA-N 0.000 description 2
- 229960002071 bepotastine Drugs 0.000 description 2
- 235000010290 biphenyl Nutrition 0.000 description 2
- 239000004305 biphenyl Substances 0.000 description 2
- 125000006267 biphenyl group Chemical group 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229960001803 cetirizine Drugs 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960002881 clemastine Drugs 0.000 description 2
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 2
- 229960002544 cloperastine Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229940108928 copper Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 2
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 2
- 229940005636 dl- methylephedrine Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960001971 ebastine Drugs 0.000 description 2
- MJJALKDDGIKVBE-UHFFFAOYSA-N ebastine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(=O)CCCN1CCC(OC(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MJJALKDDGIKVBE-UHFFFAOYSA-N 0.000 description 2
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229960002179 ephedrine Drugs 0.000 description 2
- 229960003449 epinastine Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 229960003592 fexofenadine Drugs 0.000 description 2
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- JTLXCMOFVBXEKD-FOWTUZBSSA-N fursultiamine Chemical compound C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N JTLXCMOFVBXEKD-FOWTUZBSSA-N 0.000 description 2
- 229950006836 fursultiamine Drugs 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 239000005554 hypnotics and sedatives Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229960003088 loratadine Drugs 0.000 description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960002698 oxatomide Drugs 0.000 description 2
- BAINIUMDFURPJM-UHFFFAOYSA-N oxatomide Chemical compound O=C1NC2=CC=CC=C2N1CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BAINIUMDFURPJM-UHFFFAOYSA-N 0.000 description 2
- 210000005037 parasympathetic nerve Anatomy 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940021213 phenylephrine hydrochloride 10 mg Drugs 0.000 description 2
- 229940063599 phenylephrine hydrochloride 15 mg Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960003910 promethazine Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229960003908 pseudoephedrine Drugs 0.000 description 2
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 description 2
- 229940110132 pseudoephedrine hydrochloride 75 mg Drugs 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical class C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 229940127230 sympathomimetic drug Drugs 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 229960003223 tripelennamine Drugs 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- SFZVXTJDDOYGIS-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)-methylazanium;chloride Chemical compound Cl.CNC(CS)C(O)=O SFZVXTJDDOYGIS-UHFFFAOYSA-N 0.000 description 1
- CAVQBDOACNULDN-NRCOEFLKSA-N (1s,2s)-2-(methylamino)-1-phenylpropan-1-ol;sulfuric acid Chemical compound OS(O)(=O)=O.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1.CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 CAVQBDOACNULDN-NRCOEFLKSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 description 1
- DKSZLDSPXIWGFO-BLOJGBSASA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,7,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;phosphoric acid;hydrate Chemical compound O.OP(O)(O)=O.OP(O)(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC.C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC DKSZLDSPXIWGFO-BLOJGBSASA-N 0.000 description 1
- DJAHKBBSJCDSOZ-AJLBTXRUSA-N (5z,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one;(5e,9e,13e)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C/CCC(C)=O.CC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O DJAHKBBSJCDSOZ-AJLBTXRUSA-N 0.000 description 1
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 1
- FWLKKPKZQYVAFR-LVEZLNDCSA-N (e)-but-2-enedioic acid;1-(2-ethoxyethyl)-2-(4-methyl-1,4-diazepan-1-yl)benzimidazole Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O.N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 FWLKKPKZQYVAFR-LVEZLNDCSA-N 0.000 description 1
- QOHTWPYSDMTOPU-UHFFFAOYSA-N 1-(4-iodophenyl)sulfonyl-3-propylurea Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(I)C=C1 QOHTWPYSDMTOPU-UHFFFAOYSA-N 0.000 description 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- WYUYEJNGHIOFOC-VVTVMFAVSA-N 2-[(z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridine;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C\CN1CCCC1 WYUYEJNGHIOFOC-VVTVMFAVSA-N 0.000 description 1
- GZECPKFYQHSCEV-UHFFFAOYSA-N 2-[2-benzhydryloxyethyl(methyl)amino]-1-phenylpropan-1-ol;phosphoric acid Chemical compound OP(O)(O)=O.C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN(C)C(C)C(O)C1=CC=CC=C1 GZECPKFYQHSCEV-UHFFFAOYSA-N 0.000 description 1
- FSSICIQKZGUEAE-UHFFFAOYSA-N 2-[benzyl(pyridin-2-yl)amino]ethyl-dimethylazanium;chloride Chemical compound Cl.C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 FSSICIQKZGUEAE-UHFFFAOYSA-N 0.000 description 1
- CMCCHHWTTBEZNM-UHFFFAOYSA-N 2-bromo-N-carbamoyl-3-methylbutanamide Chemical compound CC(C)C(Br)C(=O)NC(N)=O CMCCHHWTTBEZNM-UHFFFAOYSA-N 0.000 description 1
- WQOYJMWVNIGIQR-UHFFFAOYSA-N 3-(dithiophen-2-ylmethylidene)-1-methylpiperidine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1N(C)CCCC1=C(C=1SC=CC=1)C1=CC=CS1 WQOYJMWVNIGIQR-UHFFFAOYSA-N 0.000 description 1
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 description 1
- CDQGZJGHIVUWQA-UHFFFAOYSA-N 4-[2-(4-hydroxy-3,5-dimethylphenyl)butan-2-yl]-2,6-dimethylphenol Chemical compound C=1C(C)=C(O)C(C)=CC=1C(C)(CC)C1=CC(C)=C(O)C(C)=C1 CDQGZJGHIVUWQA-UHFFFAOYSA-N 0.000 description 1
- QOLHOCYZKJILAV-UHFFFAOYSA-N 5-[(3-carboxy-4-hydroxyphenyl)methyl]-2-hydroxybenzoic acid;n,n-dimethyl-1-phenothiazin-10-ylpropan-2-amine Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1.C1=C(O)C(C(=O)O)=CC(CC=2C=C(C(O)=CC=2)C(O)=O)=C1 QOLHOCYZKJILAV-UHFFFAOYSA-N 0.000 description 1
- 241000332371 Abutilon x hybridum Species 0.000 description 1
- 244000066764 Ailanthus triphysa Species 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241001106067 Atropa Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- VOPDPHUPTGYSRE-UHFFFAOYSA-N C(C(OC1C2=CC=CC=C2)OC1C1=CC=CC=C1)N1CCCCC1.I Chemical compound C(C(OC1C2=CC=CC=C2)OC1C1=CC=CC=C1)N1CCCCC1.I VOPDPHUPTGYSRE-UHFFFAOYSA-N 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- WKZITTRQXFNUNO-UHFFFAOYSA-N Difeterol hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)OCCN(C)C(C)C(O)C1=CC=CC=C1 WKZITTRQXFNUNO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JFKJWWJOCJHMGV-WCCKRBBISA-N Ethyl L-cysteine hydrochloride Chemical compound Cl.CCOC(=O)[C@@H](N)CS JFKJWWJOCJHMGV-WCCKRBBISA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 244000061408 Eugenia caryophyllata Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- ZPACYDRSPFRDHO-ROBAGEODSA-N Gefarnate Chemical compound CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(=O)OC\C=C(/C)CCC=C(C)C ZPACYDRSPFRDHO-ROBAGEODSA-N 0.000 description 1
- 229920001386 Gefarnate Polymers 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 241001562712 Muhlenbergia rigens Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 240000007695 Nandina domestica Species 0.000 description 1
- 206010030111 Oedema mucosal Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- WXAYTPABEADAAB-UHFFFAOYSA-N Oxyphencyclimine hydrochloride Chemical compound Cl.CN1CCCN=C1COC(=O)C(O)(C=1C=CC=CC=1)C1CCCCC1 WXAYTPABEADAAB-UHFFFAOYSA-N 0.000 description 1
- 241000736199 Paeonia Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- FFFPYJTVNSSLBQ-UHFFFAOYSA-N Phenolphthalin Chemical class OC(=O)C1=CC=CC=C1C(C=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 FFFPYJTVNSSLBQ-UHFFFAOYSA-N 0.000 description 1
- 241000218657 Picea Species 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 235000009308 Rhexia virginica Nutrition 0.000 description 1
- MJNIWUJSIGSWKK-BBANNHEPSA-N Riboflavin butyrate Chemical compound CCCC(=O)OC[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@@H](OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-BBANNHEPSA-N 0.000 description 1
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- YDBYJHTYSHBBAU-YFKPBYRVSA-N S-methyl-L-methioninate Chemical compound C[S+](C)CC[C@H](N)C([O-])=O YDBYJHTYSHBBAU-YFKPBYRVSA-N 0.000 description 1
- SKZKKFZAGNVIMN-UHFFFAOYSA-N Salicilamide Chemical compound NC(=O)C1=CC=CC=C1O SKZKKFZAGNVIMN-UHFFFAOYSA-N 0.000 description 1
- 108010038346 Seaprose S Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- UKNGDQSYPNBJAO-UHFFFAOYSA-N Tiaramide hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- YMEBNAABDXLAJE-GPAWKIAZSA-N [(e)-4-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-3-[[(e)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-butanoyloxypent-2-en-3-yl]disulfanyl]pent-3-enyl] butanoate Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(/CCOC(=O)CCC)SS\C(CCOC(=O)CCC)=C(/C)N(C=O)CC1=CN=C(C)N=C1N YMEBNAABDXLAJE-GPAWKIAZSA-N 0.000 description 1
- JVOGSHDZLOJKKR-MXFMKSRJSA-I [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O Chemical compound [Na+].[Na+].[Na+].[Mg++].CCc1c(C)c2cc3[n-]c(c(C)c3C=C)c(C)c3nc(C[C@H]3CCC([O-])=O)c(CC([O-])=O)c3[n-]c(cc1n2)c(C)c3C([O-])=O JVOGSHDZLOJKKR-MXFMKSRJSA-I 0.000 description 1
- AMZWNNKNOQSBOP-UHFFFAOYSA-M [n'-(2,5-dioxoimidazolidin-4-yl)carbamimidoyl]oxyaluminum;dihydrate Chemical compound O.O.NC(=O)NC1N=C(O[Al])NC1=O AMZWNNKNOQSBOP-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940015825 aldioxa Drugs 0.000 description 1
- 229960003790 alimemazine Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- MANKSFVECICGLK-UHFFFAOYSA-K aloxiprin Chemical compound [OH-].[Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O MANKSFVECICGLK-UHFFFAOYSA-K 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940043673 aluminum hydroxide / calcium carbonate Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 229960000985 ambroxol hydrochloride Drugs 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229920003147 ammonioalkyl methacrylate copolymer Polymers 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229960001040 ammonium chloride Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- KSUUMAWCGDNLFK-UHFFFAOYSA-N apronal Chemical compound C=CCC(C(C)C)C(=O)NC(N)=O KSUUMAWCGDNLFK-UHFFFAOYSA-N 0.000 description 1
- 229960004459 apronal Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 229960004335 azelastine hydrochloride Drugs 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229940092732 belladonna alkaloid Drugs 0.000 description 1
- 229960002873 benfotiamine Drugs 0.000 description 1
- BTNNPSLJPBRMLZ-LGMDPLHJSA-N benfotiamine Chemical compound C=1C=CC=CC=1C(=O)SC(/CCOP(O)(O)=O)=C(/C)N(C=O)CC1=CN=C(C)N=C1N BTNNPSLJPBRMLZ-LGMDPLHJSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 229960002335 bromhexine hydrochloride Drugs 0.000 description 1
- HOZOZZFCZRXYEK-GSWUYBTGSA-M butylscopolamine bromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-GSWUYBTGSA-M 0.000 description 1
- RCQXSQPPHJPGOF-UHFFFAOYSA-N caffeine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C RCQXSQPPHJPGOF-UHFFFAOYSA-N 0.000 description 1
- 229960002031 caffeine citrate Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 229960000456 carbinoxamine maleate Drugs 0.000 description 1
- GVNWHCVWDRNXAZ-BTJKTKAUSA-N carbinoxamine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 GVNWHCVWDRNXAZ-BTJKTKAUSA-N 0.000 description 1
- 229940015480 carbinoxamine maleate 6 mg Drugs 0.000 description 1
- 229960004399 carbocisteine Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 229960004342 cetirizine hydrochloride Drugs 0.000 description 1
- FHRSHSOEWXUORL-HDJSIYSDSA-N cetraxate Chemical compound C1C[C@@H](C[NH3+])CC[C@@H]1C(=O)OC1=CC=C(CCC([O-])=O)C=C1 FHRSHSOEWXUORL-HDJSIYSDSA-N 0.000 description 1
- 229950009533 cetraxate Drugs 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229940013684 chlorpheniramine maleate 8 mg Drugs 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 229960002689 clemastine fumarate Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960004415 codeine phosphate Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 229940110321 dicyclomine hydrochloride Drugs 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 229960001056 dimemorfan Drugs 0.000 description 1
- KBEZZLAAKIIPFK-NJAFHUGGSA-N dimemorfan Chemical compound C1C2=CC=C(C)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 KBEZZLAAKIIPFK-NJAFHUGGSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- LPRLDRXGWKXRMQ-UHFFFAOYSA-N diphenylpyraline hydrochloride Chemical compound [Cl-].C1C[NH+](C)CCC1OC(C=1C=CC=CC=1)C1=CC=CC=C1 LPRLDRXGWKXRMQ-UHFFFAOYSA-N 0.000 description 1
- 229960002392 diphenylpyraline hydrochloride Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002548 epinastine hydrochloride Drugs 0.000 description 1
- 229960002561 eprazinone Drugs 0.000 description 1
- BSHWLCACYCVCJE-UHFFFAOYSA-N eprazinone Chemical compound C=1C=CC=CC=1C(OCC)CN(CC1)CCN1CC(C)C(=O)C1=CC=CC=C1 BSHWLCACYCVCJE-UHFFFAOYSA-N 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229960000514 ethenzamide Drugs 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- QPMJENKZJUFOON-PLNGDYQASA-N ethyl (z)-3-chloro-2-cyano-4,4,4-trifluorobut-2-enoate Chemical compound CCOC(=O)C(\C#N)=C(/Cl)C(F)(F)F QPMJENKZJUFOON-PLNGDYQASA-N 0.000 description 1
- YRSGDLIATOURQO-UHFFFAOYSA-N ethyl 4-acetyl-5-oxohexanoate Chemical compound CCOC(=O)CCC(C(C)=O)C(C)=O YRSGDLIATOURQO-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940061262 ethyl cysteine hydrochloride Drugs 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- PFAXACNYGZVKMX-UHFFFAOYSA-N fenethazine Chemical compound C1=CC=C2N(CCN(C)C)C3=CC=CC=C3SC2=C1 PFAXACNYGZVKMX-UHFFFAOYSA-N 0.000 description 1
- 229950007454 fenethazine Drugs 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 229960003779 gefarnate Drugs 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229960002146 guaifenesin Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- POOYFSLWYLDQMD-UHFFFAOYSA-N heptacalcium;zinc Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Zn+2] POOYFSLWYLDQMD-UHFFFAOYSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- RAOHHYUBMJLHNC-UHFFFAOYSA-N methixene hydrochloride Chemical compound [H+].O.[Cl-].C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 RAOHHYUBMJLHNC-UHFFFAOYSA-N 0.000 description 1
- 229940098953 methixene hydrochloride Drugs 0.000 description 1
- 229960000659 methoxyphenamine hydrochloride Drugs 0.000 description 1
- FGSJNNQVSUVTPW-UHFFFAOYSA-N methoxyphenamine hydrochloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1OC FGSJNNQVSUVTPW-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001383 methylscopolamine Drugs 0.000 description 1
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 description 1
- GFEGEDUIIYDMOX-BMJUYKDLSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(z)-3-[[(z)-2-[(4-amino-2-methylpyrimidin-5-yl)methyl-formylamino]-5-hydroxypent-2-en-3-yl]disulfanyl]-5-hydroxypent-2-en-2-yl]formamide Chemical compound C=1N=C(C)N=C(N)C=1CN(C=O)C(\C)=C(CCO)/SSC(/CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N GFEGEDUIIYDMOX-BMJUYKDLSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229950005216 napadisilate Drugs 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229960000251 oxyphencyclimine hydrochloride Drugs 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- GHZNWXGYWUBLLI-UHFFFAOYSA-N p-Lactophenetide Chemical compound CCOC1=CC=C(NC(=O)C(C)O)C=C1 GHZNWXGYWUBLLI-UHFFFAOYSA-N 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001734 parasympathetic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 229960003436 pentoxyverine Drugs 0.000 description 1
- 229940018687 phenylephrine hydrochloride 30 mg Drugs 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- FFNMBRCFFADNAO-UHFFFAOYSA-N pirenzepine hydrochloride Chemical compound [H+].[H+].[Cl-].[Cl-].C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 FFNMBRCFFADNAO-UHFFFAOYSA-N 0.000 description 1
- 229960000293 pirenzepine hydrochloride Drugs 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- QFRKWSPTCBGLSU-UHFFFAOYSA-M potassium 4-hydroxy-3-methoxybenzene-1-sulfonate Chemical compound [K+].COC1=CC(S([O-])(=O)=O)=CC=C1O QFRKWSPTCBGLSU-UHFFFAOYSA-M 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 229940069505 potassium guaiacolsulfonate Drugs 0.000 description 1
- 229960002244 promethazine hydrochloride Drugs 0.000 description 1
- XXPDBLUZJRXNNZ-UHFFFAOYSA-N promethazine hydrochloride Chemical compound Cl.C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 XXPDBLUZJRXNNZ-UHFFFAOYSA-N 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- 229950007142 prosultiamine Drugs 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229960004159 pseudoephedrine sulfate Drugs 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960000581 salicylamide Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229950009846 scopolamine butylbromide Drugs 0.000 description 1
- 229960004499 scopolamine hydrobromide Drugs 0.000 description 1
- WTGQALLALWYDJH-MOUKNHLCSA-N scopolamine hydrobromide (anhydrous) Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 description 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 1
- 229940048730 senega Drugs 0.000 description 1
- 229950000112 serrapeptase Drugs 0.000 description 1
- 108010038132 serratiopeptidase Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940068459 sodium pantothenate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- GFWRVVCDTLRWPK-KPKJPENVSA-N sofalcone Chemical compound C1=CC(OCC=C(C)C)=CC=C1\C=C\C(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O GFWRVVCDTLRWPK-KPKJPENVSA-N 0.000 description 1
- 229950004782 sofalcone Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950006156 teprenone Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960001385 thiamine disulfide Drugs 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- 229960001593 triprolidine hydrochloride Drugs 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は医薬組成物に関する。より詳細には、特に鼻閉などの鼻炎症状の改善に有用な医薬組成物に関する。 The present invention relates to a pharmaceutical composition. More particularly, the present invention relates to a pharmaceutical composition useful for improving nasal inflammation symptoms such as nasal congestion.
鼻炎は、くしゃみ、鼻みず(鼻汁過多)、鼻づまり(鼻閉)等を症状とする疾患である。これらの症状は単に不快であるのみならず、仕事に集中できなくなったり睡眠をさまたげたりして、日常生活に大きな影響を及ぼす。特に鼻閉は、息苦しさが持続し、また、口呼吸によって呼吸器感染症に罹患する危険性が増すことからも、早期の改善が望まれる。 Rhinitis is a disease with symptoms such as sneezing, nasal congestion (excessive nasal discharge), and nasal congestion (nasal congestion). These symptoms are not only unpleasant, but also have a major impact on daily life by being unable to concentrate on work or sleeping. In particular, nasal congestion is desired to be improved early because suffocation persists and the risk of developing respiratory infections due to mouth breathing increases.
鼻炎の原因は、かぜによるウイルス感染や細菌感染によるもの(急性鼻炎)、花粉やハウスダスト等によって引き起こされるアレルギー反応によるもの(アレルギー性鼻炎)など多岐に渡る。そのため、鼻炎の治療・改善は、症状に応じた対処療法が中心となっている。鼻炎の症状のなかでも、特に鼻閉に対しては、α作用に基づく鼻粘膜収縮を期待して、シュードエフェドリン、メチルエフェドリン、フェニレフリン、フェニルプロパノールアミン等の交感神経興奮剤が用いられている。例えば、特許文献1には、エフェドリンの光学活性体であるシュードエフェドリンとフェニレフリンとベラドンナ総アルカロイドを含有する鼻炎症状の治療等のための医薬組成物が開示されており、当該文献には、d−塩酸シュードエフェドリンと塩酸フェニレフリンを組み合わせた場合の鼻閉改善に関する試験結果も記載されている。
しかしながら、斯かる試験結果において、d−塩酸シュードエフェドリンと塩酸フェニレフリンを組み合わせた場合(比較例1)と各成分単独の場合(比較例3、4)とでは鼻閉改善評価に殆ど差が無く、特に服用後短時間(30分後)では、d−塩酸シュードエフェドリンと塩酸フェニレフリンを組み合わせた場合と塩酸フェニレフリン単独の場合とで鼻閉改善評価が全く同一となっており、エフェドリンとフェニレフリンとの組み合わせでは、鼻閉抑制作用の増強が殆ど奏されないことが明らかにされている。
There are various causes of rhinitis, such as those caused by viral infection or bacterial infection caused by cold (acute rhinitis), and those caused by allergic reactions caused by pollen or house dust (allergic rhinitis). Therefore, treatment and improvement of rhinitis center on coping therapy according to symptoms. Among the symptoms of rhinitis, particularly for nasal congestion, sympathomimetic agents such as pseudoephedrine, methylephedrine, phenylephrine, phenylpropanolamine and the like are used with the expectation of nasal mucosal contraction based on α action. For example, Patent Document 1 discloses a pharmaceutical composition for the treatment of nasal inflammation and the like, which contains pseudoephedrine, phenylephrine, and belladonna total alkaloids, which are optically active ephedrines. The test results concerning improvement of nasal congestion when pseudoephedrine hydrochloride and phenylephrine hydrochloride are combined are also described.
However, in such test results, there is almost no difference in nasal closure improvement evaluation when d-pseudoephedrine hydrochloride and phenylephrine hydrochloride are combined (Comparative Example 1) and when each component is alone (Comparative Examples 3 and 4). In particular, in the short time after taking (30 minutes), the combination of ephedrine and phenylephrine has the same evaluation of improvement in nasal closure when d-pseudoephrine hydrochloride and phenylephrine hydrochloride are combined with phenylephrine hydrochloride alone. It has been clarified that almost no enhancement of the nasal obstruction suppression effect is achieved.
本発明の課題は、優れた薬理作用を有する、特に鼻閉などの鼻炎症状の改善作用に優れる医薬組成物の提供にある。 An object of the present invention is to provide a pharmaceutical composition having an excellent pharmacological action, in particular, an action for improving nasal inflammation such as nasal congestion.
そこで、本発明者は鋭意検討したところ、驚くべきことに、エフェドリンと比較して薬効がよりマイルドであるとされるメチルエフェドリンをフェニレフリンと組み合わせると、格別に優れた鼻閉抑制作用等の薬理作用が奏されることを見出し、本発明を完成した。 Therefore, the present inventor has intensively studied, and surprisingly, when methylephedrine, which is said to have a milder drug effect than ephedrine, is combined with phenylephrine, pharmacological action such as nasal obstruction inhibitory action is excellent. The present invention has been completed.
すなわち、本発明は、次の成分(A)及び(B):
(A)メチルエフェドリン及びその塩よりなる群から選ばれる1種以上;
(B)フェニレフリン及びその塩よりなる群から選ばれる1種以上;
を含有する医薬組成物を提供するものである。
That is, the present invention includes the following components (A) and (B):
(A) one or more selected from the group consisting of methylephedrine and salts thereof;
(B) one or more selected from the group consisting of phenylephrine and salts thereof;
The pharmaceutical composition containing this is provided.
また、本発明は、フェニレフリン及びその塩よりなる群から選ばれる1種以上を含む医薬組成物の鼻炎症状治療又は緩和作用を増強させるために使用される鼻炎症状治療又は緩和作用増強剤であって、メチルエフェドリン及びその塩よりなる群から選ばれる1種以上を有効成分とする増強剤を提供するものである。 The present invention also relates to a nasal inflammation-like treatment or alleviating action enhancer used for enhancing the nasal inflammation-like treatment or alleviation action of a pharmaceutical composition comprising one or more selected from the group consisting of phenylephrine and a salt thereof. And an enhancer comprising as an active ingredient at least one selected from the group consisting of methylephedrine and salts thereof.
さらに、本発明は、メチルエフェドリン及びその塩よりなる群から選ばれる1種以上を含む医薬組成物の鼻炎症状治療又は緩和作用を増強させるために使用される鼻炎症状治療又は緩和作用増強剤であって、フェニレフリン及びその塩よりなる群から選ばれる1種以上を有効成分とする増強剤を提供するものである。 Furthermore, the present invention is a nasal inflammation-like therapeutic or alleviating action enhancer used for enhancing a nasal inflammation-like therapeutic or alleviating action of a pharmaceutical composition comprising one or more selected from the group consisting of methylephedrine and a salt thereof. Thus, an enhancer comprising one or more selected from the group consisting of phenylephrine and a salt thereof as an active ingredient is provided.
メチルエフェドリン及びその塩から選ばれる1種以上と、フェニレフリン及びその塩から選ばれる1種以上との組み合わせは、格別に優れた鼻閉抑制作用を有する。従って、本発明によれば、優れた薬理作用を有する医薬組成物を提供することができる。 A combination of at least one selected from methylephedrine and a salt thereof and at least one selected from phenylephrine and a salt thereof has a particularly excellent nasal obstruction inhibitory action. Therefore, according to the present invention, a pharmaceutical composition having an excellent pharmacological action can be provided.
<成分(A)>
メチルエフェドリンには不斉炭素が存するため、光学異性体が存するが、本発明の「メチルエフェドリン」はいずれの光学異性体をも含み、単一の光学異性体でもよく、各種光学異性体の混合物でもよい。また、本発明の「メチルエフェドリンの塩」としては、薬学上許容される無機酸や有機酸の塩が挙げられ、具体的には例えば、塩酸塩、硫酸塩、サッカリン塩等が挙げられる。こうしたメチルエフェドリンやその塩の例としては、具体的には例えば、l−メチルエフェドリン塩酸塩、dl−メチルエフェドリン塩酸塩、l−メチルエフェドリンサッカリン塩、dl−メチルエフェドリンサッカリン塩などが挙げられる。
<Component (A)>
Since methyl ephedrine has an asymmetric carbon, optical isomers exist. However, the “methyl ephedrine” of the present invention includes any optical isomer, and may be a single optical isomer or a mixture of various optical isomers. But you can. In addition, examples of the “methylephedrine salt” of the present invention include pharmaceutically acceptable salts of inorganic acids and organic acids, and specific examples include hydrochlorides, sulfates, saccharin salts and the like. Specific examples of such methyl ephedrine and salts thereof include, for example, 1-methyl ephedrine hydrochloride, dl-methyl ephedrine hydrochloride, 1-methyl ephedrine saccharin salt, dl-methyl ephedrine saccharin salt and the like.
本発明において、「メチルエフェドリン及びその塩よりなる群から選ばれる1種以上」としては、l−メチルエフェドリン塩酸塩、dl−メチルエフェドリン塩酸塩、l−メチルエフェドリンサッカリン塩及びdl−メチルエフェドリンサッカリン塩よりなる群から選ばれる1種以上が好ましく、l−メチルエフェドリン塩酸塩及びdl−メチルエフェドリン塩酸塩よりなる群から選ばれる1種以上がより好ましく、dl−メチルエフェドリン塩酸塩がさらに好ましく、第十六改正日本薬局方に収載のdl−メチルエフェドリン塩酸塩が特に好ましい。
なお、メチルエフェドリン及びその塩よりなる群から選ばれる1種以上は、公知の化合物であり、公知の方法により製造できるほか、市販のものを使用することができる。市販品としては例えば、dl−メチルエフェドリン塩酸塩(アルプス薬品工業(株))などが挙げられる。
In the present invention, “one or more selected from the group consisting of methylephedrine and a salt thereof” includes l-methylephedrine hydrochloride, dl-methylephedrine hydrochloride, l-methylephedrine saccharin salt, and dl-methylephedrine saccharin salt. At least one selected from the group consisting of 1-methylephedrine hydrochloride and dl-methylephedrine hydrochloride is more preferable, dl-methylephedrine hydrochloride is more preferable, The dl-methylephedrine hydrochloride listed in the Six Revised Japanese Pharmacopoeia is particularly preferred.
In addition, 1 or more types chosen from the group which consists of methylephedrine and its salt are well-known compounds, In addition to being able to manufacture by a well-known method, a commercially available thing can be used. Examples of commercially available products include dl-methylephedrine hydrochloride (Alps Pharmaceutical Co., Ltd.).
本発明の医薬組成物におけるメチルエフェドリン及びその塩よりなる群から選ばれる1種以上の含有量は特に限定されず、鼻閉抑制作用等に応じて適宜検討して決定すればよい。例えば、1日当たり、メチルエフェドリン及びその塩よりなる群から選ばれる1種以上を1〜200mg、より好適には10〜150mg、更に好適には20〜110mg、更に好適には22.5〜90mg、特に好適には25〜65mg服用できる量を含有せしめることができる。本発明においては、鼻閉抑制作用の観点から、医薬組成物全質量に対して0.5〜30質量%含有するのが好ましく、1〜25質量%含有するのがより好ましく、3〜20質量%含有するのがさらに好ましく、5〜15質量%含有するのが特に好ましい。 The content of one or more selected from the group consisting of methylephedrine and a salt thereof in the pharmaceutical composition of the present invention is not particularly limited, and may be determined by appropriately examining according to the nasal obstruction inhibitory action and the like. For example, 1 to 200 mg, more preferably 10 to 150 mg, more preferably 20 to 110 mg, more preferably 22.5 to 90 mg, selected from the group consisting of methylephedrine and a salt thereof per day. Particularly preferably, it can contain an amount that can be taken from 25 to 65 mg. In this invention, it is preferable to contain 0.5-30 mass% with respect to the total mass of a pharmaceutical composition from a viewpoint of a nasal obstruction inhibitory action, It is more preferable to contain 1-25 mass%, 3-20 mass % Is more preferable, and 5 to 15% by mass is particularly preferable.
<成分(B)>
本発明の「フェニレフリンの塩」としては、薬学上許容される無機酸や有機酸の塩が挙げられ、具体的には例えば、塩酸塩等が挙げられる。本発明において、「フェニレフリン及びその塩よりなる群から選ばれる1種以上」としては、フェニレフリン塩酸塩が好ましく、第十六改正日本薬局方に収載のフェニレフリン塩酸塩が特に好ましい。
なお、フェニレフリン及びその塩よりなる群から選ばれる1種以上は公知の化合物であり、公知の方法により製造できるほか、市販のものを使用することができる。市販品としては例えば、フェニレフリン塩酸塩(岩城製薬(株))などが挙げられる。
<Component (B)>
Examples of the “phenylephrine salt” of the present invention include pharmaceutically acceptable inorganic acid and organic acid salts, and specific examples include hydrochloride and the like. In the present invention, “one or more selected from the group consisting of phenylephrine and a salt thereof” is preferably phenylephrine hydrochloride, and phenylephrine hydrochloride listed in the 16th revision Japanese Pharmacopoeia is particularly preferable.
In addition, 1 or more types chosen from the group which consists of phenylephrine and its salt are well-known compounds, besides being able to manufacture by a well-known method, a commercially available thing can be used. As a commercial item, phenylephrine hydrochloride (Iwaki Pharmaceutical Co., Ltd.) etc. are mentioned, for example.
本発明の医薬組成物におけるフェニレフリン及びその塩よりなる群から選ばれる1種以上の含有量は特に限定されず、鼻閉抑制作用等に応じて適宜検討して決定すればよい。例えば、1日当たり、フェニレフリン及びその塩よりなる群から選ばれる1種以上を1〜50mg、より好適には2〜40mg、更に好適には3〜30mg、更に好適には4〜20mg、特に好適には5〜15mg服用できる量を含有せしめることができる。本発明においては、鼻閉抑制作用の観点から、医薬組成物全質量に対して0.01〜15質量%含有するのが好ましく、0.1〜10質量%含有するのがより好ましく、0.5〜7.5質量%含有するのがさらに好ましく、1〜5質量%含有するのが特に好ましい。 The content of one or more selected from the group consisting of phenylephrine and a salt thereof in the pharmaceutical composition of the present invention is not particularly limited, and may be determined by appropriately examining according to the nasal obstruction inhibitory action or the like. For example, 1 to 50 mg, more preferably 2 to 40 mg, more preferably 3 to 30 mg, more preferably 4 to 20 mg, particularly preferably 1 or more kinds selected from the group consisting of phenylephrine and a salt thereof per day. Can contain an amount of 5 to 15 mg. In the present invention, from the viewpoint of the nasal obstruction inhibitory action, it is preferably contained in an amount of 0.01 to 15% by mass, more preferably 0.1 to 10% by mass relative to the total mass of the pharmaceutical composition. It is more preferable to contain 5-7.5 mass%, and it is especially preferable to contain 1-5 mass%.
本発明の医薬組成物における(A)メチルエフェドリン及びその塩よりなる群から選ばれる1種以上と、(B)フェニレフリン及びその塩よりなる群から選ばれる1種以上との含有質量比率〔(B)/(A)〕は特に限定されないが、鼻閉抑制作用の観点から、0.005〜2が好ましく、0.01〜1がより好ましく、0.05〜0.75がさらに好ましく、0.1〜0.5が特に好ましい。 In the pharmaceutical composition of the present invention, (A) one or more selected from the group consisting of methylephedrine and a salt thereof, and (B) a mass ratio of one or more selected from the group consisting of phenylephrine and a salt thereof [(B ) / (A)] is not particularly limited, but is preferably 0.005 to 2, more preferably 0.01 to 1, still more preferably 0.05 to 0.75, from the viewpoint of nasal obstruction suppression action. 1 to 0.5 is particularly preferable.
<成分(C)>
本発明の医薬組成物においては、鼻閉抑制作用の観点から、さらに(C)抗ヒスタミン剤を含有するのが好ましい。
本発明で使用される「抗ヒスタミン剤」としては、ヒスタミンH1受容体拮抗作用を有するものであれば特に限定されるものではなく、具体的には例えば、アゼラスチン、アリメマジン、イソチペンジル、イプロヘプチン、エバスチン、エピナスチン、エメダスチン、オキサトミド、オロパタジン、カルビノキサミン、クレマスチン、クロルフェニラミン、ケトチフェン、ジフェテロール、ジフェニルピラリン、ジフェンヒドラミン、シプロヘプタジン、セチリジン、トリプロリジン、トリペレナミン、トンジルアミン、フェキソフェナジン、フェネタジン、プロメタジン、ベポタスチン、ホモクロルシクリジン、メキタジン、メトジラジン、メブヒドロリン及びロラタジン並びにこれらの塩からなる群より選ばれる1種以上が挙げられる。なお、塩としては、無機酸や有機酸、無機塩基や有機塩基等との塩が挙げられ、例えば、塩酸塩、酒石酸塩、マレイン酸塩、フマル酸塩、ジフェニルジスルホン酸塩、テオクル酸塩、サリチル酸塩、タンニン酸塩、ベシル酸塩、ナパジシル酸塩、リン酸塩等が挙げられる。また、抗ヒスタミン剤の化学構造中、不斉炭素が存する場合は、種々の光学異性体が存するが、本発明においては、いずれの光学異性体をも含み、単一の光学異性体でもよく、各種光学異性体の混合物でもよい。さらに、抗ヒスタミン剤は溶媒和物の状態にあってもよく、上記各種化合物やその塩と水やアルコール等との溶媒和物も「抗ヒスタミン剤」に含まれる(従って、「各種化合物及びその塩よりなる群から選ばれる1種以上」には、当該化合物やその塩の溶媒和物も包含される。)。
なお、抗ヒスタミン剤は、公知の化合物であり、公知の方法により製造できるほか、市販のものを使用することができる。
<Ingredient (C)>
The pharmaceutical composition of the present invention preferably further contains (C) an antihistamine from the viewpoint of the nasal obstruction inhibitory action.
The “antihistamine” used in the present invention is not particularly limited as long as it has a histamine H 1 receptor antagonistic action, and specifically includes, for example, azelastine, alimemazine, istipendil, iproheptin, ebastine, epinastine. , Emedastine, oxatomide, olopatadine, carbinoxamine, clemastine, chlorpheniramine, ketotifen, dipheterol, diphenylpyrine, diphenhydramine, cyproheptadine, cetirizine, triprolysine, tripelenamine, tongylamine, fexofenadine, phenetadine, promethadine, promethazine Examples thereof include one or more selected from the group consisting of mequitazine, methodirazine, mebhydroline, loratadine, and salts thereof. Examples of the salt include salts with inorganic acids, organic acids, inorganic bases, organic bases, etc., for example, hydrochloride, tartrate, maleate, fumarate, diphenyldisulfonate, teocrate, Examples include salicylate, tannate, besylate, napadisylate, phosphate, and the like. In the chemical structure of the antihistamine, when an asymmetric carbon exists, various optical isomers exist. In the present invention, any optical isomer may be included, and a single optical isomer may be used. It may be a mixture of isomers. Further, the antihistamine may be in the form of a solvate, and solvates of the above various compounds and salts thereof with water, alcohol, etc. are also included in the “antihistamine” (therefore, the group consisting of “various compounds and salts thereof”). The term “one or more selected from the above” includes solvates of the compounds and salts thereof.)
In addition, an antihistamine is a well-known compound, and can manufacture it by a well-known method, and can use a commercially available thing.
本発明に用いられる抗ヒスタミン剤としては、鼻閉抑制作用の観点から、アゼラスチン塩酸塩等のアゼラスチン及びその塩よりなる群から選ばれる1種以上;アリメマジン酒石酸塩等のアリメマジン及びその塩よりなる群から選ばれる1種以上;イソチペンジル塩酸塩等のイソチペンジル及びその塩よりなる群から選ばれる1種以上;イプロヘプチン塩酸塩等のイプロへプチン及びその塩よりなる群から選ばれる1種以上;エバスチン及びその塩よりなる群から選ばれる1種以上;エピナスチン塩酸塩等のエピナスチン及びその塩よりなる群から選ばれる1種以上;エメダスチンフマル酸塩等のエメダスチン及びその塩よりなる群から選ばれる1種以上;オキサトミド及びその塩よりなる群から選ばれる1種以上;オロパタジン塩酸塩等のオロパタジン及びその塩よりなる群から選ばれる1種以上;カルビノキサミンジフェニルジスルホン酸塩、カルビノキサミンマレイン酸塩等のカルビノキサミン及びその塩よりなる群から選ばれる1種以上;クレマスチンフマル酸塩等のクレマスチン及びその塩よりなる群から選ばれる1種以上;d−クロルフェニラミンマレイン酸塩、dl−クロルフェニラミンマレイン酸塩等のクロルフェニラミン及びその塩よりなる群から選ばれる1種以上;ケトチフェンフマル酸塩等のケトチフェン及びその塩よりなる群から選ばれる1種以上;ジフェテロール塩酸塩、ジフェテロールリン酸塩等のジフェテロール及びその塩よりなる群から選ばれる1種以上;ジフェニルピラリン塩酸塩、ジフェニルピラリンテオクル酸塩等のジフェニルピラリン及びその塩よりなる群から選ばれる1種以上;ジフェンヒドラミン塩酸塩、ジフェンヒドラミンサリチル酸塩、ジフェンヒドラミンタンニン酸塩等のジフェンヒドラミン及びその塩よりなる群から選ばれる1種以上;シプロヘプタジン塩酸塩水和物等のシプロヘプタジン及びその塩よりなる群から選ばれる1種以上;セチリジン塩酸塩等のセチリジン及びその塩よりなる群から選ばれる1種以上;トリプロリジン塩酸塩等のトリプロリジン及びその塩よりなる群から選ばれる1種以上;トリペレナミン塩酸塩等のトリペレナミン及びその塩よりなる群から選ばれる1種以上;トンジルアミン塩酸塩等のトンジルアミン及びその塩よりなる群から選ばれる1種以上;フェキソフェナジン及びその塩よりなる群から選ばれる1種以上;フェネタジン塩酸塩等のフェネタジン及びその塩よりなる群から選ばれる1種以上;プロメタジン塩酸塩、プロメタジンメチレン二サリチル酸塩等のプロメタジン及びその塩よりなる群から選ばれる1種以上;ベポタスチンベシル酸塩等のベポタスチン及びその塩よりなる群から選ばれる1種以上;ホモクロルシクリジン塩酸塩等のホモクロルシクリジン及びその塩よりなる群から選ばれる1種以上;メキタジン及びその塩よりなる群から選ばれる1種以上;メトジラジン塩酸塩等のメトジラジン及びその塩よりなる群から選ばれる1種以上;メブヒドロリンナパジシル酸塩等のメブヒドロリン及びその塩よりなる群から選ばれる1種以上;ロラタジン及びその塩よりなる群から選ばれる1種以上等が好ましく、カルビノキサミン及びその塩よりなる群から選ばれる1種以上、クロルフェニラミン及びその塩よりなる群から選ばれる1種以上、又はメキタジン及びその塩よりなる群から選ばれる1種以上が特に好ましい。 The antihistamine used in the present invention is one or more selected from the group consisting of azelastine such as azelastine hydrochloride and a salt thereof from the viewpoint of nasal congestion inhibiting action; One or more selected from the group consisting of isothipentil such as isothipentyl hydrochloride and its salt; one or more selected from the group consisting of iproheptin and its salt such as iproheptin hydrochloride; from ebastine and its salt 1 or more selected from the group consisting of epinastine such as epinastine hydrochloride and its salt; 1 or more selected from the group consisting of emedastine and its salt such as emedastine fumarate; One or more selected from the group consisting of oxatomide and salts thereof; olopatadine hydrochloride, etc. One or more selected from the group consisting of patadine and salts thereof; one or more selected from the group consisting of carbinoxamines such as carbinoxamine diphenyl disulfonate and carbinoxamine maleate and salts thereof; and clemastine fumarate One or more selected from the group consisting of clemastine and its salts; one or more selected from the group consisting of chlorpheniramine and its salts such as d-chlorpheniramine maleate and dl-chlorpheniramine maleate; ketotifen One or more selected from the group consisting of ketotifen such as fumarate and salts thereof; one or more selected from the group consisting of dipheterol and salts thereof such as difeterol hydrochloride and difeterol phosphate; diphenylpyraline hydrochloride; Diphenyl pyralin such as diphenyl pyralin theecuronate and One or more selected from the group consisting of salts of: One or more selected from the group consisting of salts; one or more selected from the group consisting of cetirizine such as cetirizine hydrochloride and salts thereof; one or more selected from the group consisting of triprolidine such as triprolidine hydrochloride and salts thereof One or more selected from the group consisting of tripelenamine such as tripelenamine hydrochloride and its salt; one or more selected from the group consisting of tonsilamine and its salt such as tonsilamine hydrochloride; selected from the group consisting of fexofenadine and its salt One or more of which; One or more selected from the group consisting of phenetazine such as a salt and a salt thereof; one or more selected from the group consisting of promethazine and a salt thereof such as promethazine hydrochloride and promethazine methylene disalicylate; such as bepotastine besylate 1 or more selected from the group consisting of bepotastine and its salts; 1 or more selected from the group consisting of homochlorcyclidine and its salts such as homochlorcyclidine hydrochloride; 1 selected from the group consisting of mequitazine and its salts One or more species; one or more selected from the group consisting of methodirazine such as methodirazine hydrochloride and its salt; one or more selected from the group consisting of mebhydroline and its salt such as mebhydroline napadisilate; loratadine and its salt Preferably, one or more selected from the group consisting of, and selected from the group consisting of carbinoxamine and salts thereof. One or more elements, at least one member selected from the group consisting of chlorpheniramine and its salts, or one or more selected from mequitazine and the group consisting of a salt thereof are particularly preferred.
本発明の医薬組成物における成分(C)の抗ヒスタミン剤の含有量は特に限定されず、鼻閉抑制作用等に応じて適宜検討して決定すればよい。例えば、1日あたり、成分(C)の抗ヒスタミン剤を0.01〜100mg、より好適には0.03〜50mg、特に好適には0.1〜10mg服用できる量を含有せしめることができる。本発明においては、鼻閉抑制作用の観点から、医薬組成物全質量に対して0.005〜15質量%含有するのが好ましく、0.01〜10質量%含有するのがより好ましく、0.05〜5質量%含有するのがさらに好ましく、0.1〜3質量%含有するのが特に好ましい。 The content of the antihistamine of component (C) in the pharmaceutical composition of the present invention is not particularly limited, and may be determined by appropriately examining according to the nasal obstruction inhibitory action and the like. For example, 0.01 to 100 mg, more preferably 0.03 to 50 mg, and particularly preferably 0.1 to 10 mg of the antihistamine of component (C) can be contained per day. In the present invention, from the viewpoint of the nasal obstruction inhibitory action, it is preferably contained in an amount of 0.005 to 15% by mass, more preferably 0.01 to 10% by mass relative to the total mass of the pharmaceutical composition. It is more preferable to contain 05-5 mass%, and it is especially preferable to contain 0.1-3 mass%.
本発明の医薬組成物における(A)メチルエフェドリン及びその塩よりなる群から選ばれる1種以上と、(C)抗ヒスタミン剤との含有質量比率〔(C)/(A)〕は特に限定されないが、鼻閉抑制作用の観点から、0.005〜0.5が好ましく、0.01〜0.3がより好ましく、0.05〜0.25がさらに好ましく、0.1〜0.2が特に好ましい。
また、本発明の医薬組成物における(B)フェニレフリン及びその塩よりなる群から選ばれる1種以上と、(C)抗ヒスタミン剤との含有質量比率〔(C)/(B)〕は特に限定されないが、鼻閉抑制作用の観点から、0.005〜5が好ましく、0.01〜3がより好ましく、0.05〜2がさらに好ましく、0.1〜1が特に好ましい。
The content mass ratio [(C) / (A)] of (A) one or more selected from the group consisting of methylephedrine and a salt thereof in the pharmaceutical composition of the present invention and (C) an antihistamine is not particularly limited, From the viewpoint of nasal obstruction suppression action, 0.005 to 0.5 is preferable, 0.01 to 0.3 is more preferable, 0.05 to 0.25 is further preferable, and 0.1 to 0.2 is particularly preferable. .
Further, the content mass ratio [(C) / (B)] of (B) phenylephrine and a salt thereof and (C) an antihistamine in the pharmaceutical composition of the present invention is not particularly limited. From the viewpoint of the nasal obstruction inhibiting action, 0.005 to 5 is preferable, 0.01 to 3 is more preferable, 0.05 to 2 is further preferable, and 0.1 to 1 is particularly preferable.
本発明の医薬組成物の服用経路としては、経口及び経膣等の非経口が挙げられ、経口投与が好ましい。また、本発明の医薬組成物は、例えば、1日当たり1〜4回程度に分けて、食前、食間、食後、就寝前等に服用することができる。 Examples of the route of administration of the pharmaceutical composition of the present invention include oral administration and parenteral administration such as transvaginal, and oral administration is preferred. In addition, the pharmaceutical composition of the present invention can be taken, for example, before meals, between meals, after meals, before going to bed, etc., divided into about 1 to 4 times per day.
本発明の医薬組成物は、例えば、第十六改正日本薬局方 製剤総則等に記載の公知の方法により製造することができる。また、剤形は特に限定されるものではなく、固形状、半固形状、液状のいずれの形状であってもよく、その利用目的、投与経路等に応じて医薬品、医薬部外品等において通常利用される形状とすることができる。具体的には例えば、錠剤(口腔内崩壊錠、チュアブル錠、発泡錠、分散錠、溶解錠などを含む)、カプセル剤(硬カプセル剤、軟カプセル剤などを含む)、顆粒剤(発泡顆粒剤などを含む)、散剤、経口液剤(エリキシル剤、懸濁剤、乳剤、リモナーデ剤などを含む)、シロップ剤(シロップ用剤などを含む)、経口ゼリ―剤、経口フィルム剤などの経口投与する製剤;吸入剤(吸入粉末剤、吸入液剤、吸入エアゾール剤などを含む)、点鼻剤(点鼻粉末剤、点鼻液剤などを含む)、外用固形剤(外用散剤などを含む)、外用液剤(リニメント剤、ローション剤などを含む)、スプレー剤(外用エアゾール剤、ポンプスプレー剤などを含む)、軟膏剤、クリーム剤、ゲル剤、貼付剤(テープ剤、パップ剤などを含む)などの非経口投与する製剤などが挙げられる。なお、本発明の医薬組成物を製造するに当たっては、その剤形に応じて、医薬品、医薬部外品等に汎用される製剤添加物を使用することができる。 The pharmaceutical composition of the present invention can be produced by, for example, a known method described in the 16th revised Japanese Pharmacopoeia General Rules for Preparations. The dosage form is not particularly limited, and may be any of solid, semi-solid, and liquid forms, and is usually used for pharmaceuticals, quasi drugs, etc. depending on the purpose of use, administration route, etc. The shape can be used. Specifically, for example, tablets (including orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible tablets, dissolving tablets, etc.), capsules (including hard capsules, soft capsules, etc.), granules (expanded granules) Etc.), powders, oral liquids (including elixirs, suspensions, emulsions, limonades, etc.), syrups (including syrups, etc.), oral jellies, oral films, etc. Formulations; inhalants (including inhaled powders, inhalants, inhaled aerosols, etc.), nasal drops (including nasal powders, nasal solutions, etc.), external solids (including external powders), external liquids (Including liniments, lotions, etc.), sprays (including external aerosols, pump sprays, etc.), ointments, creams, gels, patches (including tapes, poultices, etc.) Made orally And the like. In producing the pharmaceutical composition of the present invention, formulation additives generally used for pharmaceuticals, quasi drugs and the like can be used depending on the dosage form.
本発明においては、服用の簡便性や薬物服用量の管理等の点で、経口投与する製剤が好ましく、錠剤、カプセル剤、顆粒剤又は散剤がより好ましく、カプセル剤がさらに好ましく、カプセル内容物が液状・ゲル状のカプセル剤(液体充填カプセル剤)が特に好ましい。内容物が液状・ゲル状のカプセル剤であれば、カプセルの崩壊とともに内容物が溶け出し速やかに吸収されるため、速やかな薬効発揮が可能である。 In the present invention, a preparation for oral administration is preferable from the viewpoint of ease of administration and management of drug dose, etc., tablets, capsules, granules or powders are more preferable, capsules are more preferable, and capsule contents are Liquid / gel capsules (liquid-filled capsules) are particularly preferred. If the content is a capsule in the form of a liquid or gel, the content dissolves and is quickly absorbed as the capsule collapses, so that a rapid medicinal effect can be achieved.
本発明の医薬組成物には、他の医薬成分として、上記以外の成分、例えば交感神経興奮剤、副交感神経遮断剤・抗コリン剤、抗炎症剤、カフェイン類、解熱鎮痛成分、鎮咳成分、ノスカピン類、去痰成分、催眠鎮静成分、ビタミン類、胃粘膜保護成分、キサンチン系成分、生薬類、漢方処方等からなる群より選ばれる1種又は2種以上を含んでいても良い。 In the pharmaceutical composition of the present invention, as other pharmaceutical ingredients, ingredients other than those described above, for example, sympathomimetic stimulants, parasympathetic blockers / anticholinsers, anti-inflammatory agents, caffeine, antipyretic analgesic ingredients, antitussive ingredients, It may contain one or more selected from the group consisting of noscapine, expectorant component, hypnotic sedative component, vitamins, gastric mucosal protective component, xanthine component, herbal medicine, Chinese herbal prescription and the like.
交感神経興奮剤としては、例えば、塩酸プソイドエフェドリン、塩酸メトキシフェナミン、硫酸プソイドエフェドリン等が挙げられる。
副交感神経遮断剤・抗コリン剤としては、例えば、オキシフェンサイクリミン塩酸塩、ジサイクロミン塩酸塩、メチキセン塩酸塩、スコポラミン臭化水素酸塩、ダツラエキス、チぺピジウム臭化物、メチルアトロピン臭化物、メチルアニソトロピン臭化物、メチルスコポラミン臭化物、メチル−l−ヒヨスチアミン臭化物、メチルベナクチジウム臭化物、ピレンゼピン塩酸塩、ブチルスコポラミン臭化物、ベラドンナアルカロイド、ベラドンナエキス、ベラドンナ総アルカロイド、ヨウ化イソプロパミド、ヨウ化ジフェニルピぺリジノメチルジオキソラン、ロートエキス、ロート根、ロート根総アルカロイドクエン酸塩等が挙げられる。
本発明の医薬組成物における副交感神経遮断剤・抗コリン剤の含有量は特に限定されないが、例えば、医薬組成物全質量に対して0.001〜0.3質量%含有するのが好ましく、0.01〜0.2質量%含有するのがより好ましい。
Examples of the sympathomimetic agent include pseudoephedrine hydrochloride, methoxyphenamine hydrochloride, pseudoephedrine sulfate, and the like.
Examples of parasympathetic nerve blockers and anticholinergics include oxyphencyclimine hydrochloride, dicyclomine hydrochloride, methixene hydrochloride, scopolamine hydrobromide, datsura extract, tipidium bromide, methyl atropine bromide, methyl anisotropin bromide Methylscopolamine bromide, methyl-1-hyostiamine bromide, methylbenactidium bromide, pirenzepine hydrochloride, butylscopolamine bromide, belladonna alkaloid, belladonna extract, belladonna total alkaloid, iodopropamide, diphenylpiperidinomethyldioxolane iodide, Funnel extract, funnel root, funnel root total alkaloid citrate and the like.
The content of the parasympathetic nerve blocker / anticholinergic agent in the pharmaceutical composition of the present invention is not particularly limited. For example, the content is preferably 0.001 to 0.3% by mass with respect to the total mass of the pharmaceutical composition. It is more preferable to contain 0.01-0.2 mass%.
抗炎症剤としては、例えば、グリチルリチン酸及びその誘導体並びにそれらの塩類(例えば、グリチルリチン酸二カリウム、グリチルリチン酸モノアンモニウム等)、カンゾウ、セアプローゼ、セミアルカリプロテイナーゼ、セラペプターゼ、トラネキサム酸、プロクターゼ、プロナーゼ、ブロメライン、リゾチーム塩酸塩等が挙げられる。
本発明の医薬組成物における抗炎症剤の含有量は特に限定されないが、例えば、医薬組成物全質量に対して1〜30質量%含有するのが好ましく、2〜15質量%含有するのがより好ましい。
カフェイン類としては、例えば、カフェイン、無水カフェイン、安息香酸ナトリウムカフェイン、クエン酸カフェイン等が挙げられる。
本発明の医薬組成物におけるカフェイン類の含有量は特に限定されないが、例えば、医薬組成物全質量に対して1〜50質量%含有するのが好ましく、5〜40質量%含有するのがより好ましい。
解熱鎮痛成分としては、例えば、アスピリン、アスピリンアルミニウム、アセトアミノフェン、イソプロピルアンチピリン、イブプロフェン、エテンザミド、サザピリン、サリチルアミド、サリチル酸ナトリウム、チアラミド塩酸塩、ラクチルフェネチジン等が挙げられる。
Examples of the anti-inflammatory agent include glycyrrhizic acid and its derivatives and salts thereof (for example, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate), licorice, seaprose, semi-alkaline proteinase, serrapeptase, tranexamic acid, proctase, pronase, bromelain And lysozyme hydrochloride.
Although content of the anti-inflammatory agent in the pharmaceutical composition of this invention is not specifically limited, For example, it is preferable to contain 1-30 mass% with respect to the pharmaceutical composition total mass, and it is more preferable to contain 2-15 mass% preferable.
Examples of caffeine include caffeine, anhydrous caffeine, sodium benzoate caffeine, and caffeine citrate.
Although the content of caffeine in the pharmaceutical composition of the present invention is not particularly limited, for example, it is preferably 1 to 50% by mass, more preferably 5 to 40% by mass with respect to the total mass of the pharmaceutical composition. preferable.
Examples of the antipyretic analgesic component include aspirin, aspirin aluminum, acetaminophen, isopropylantipyrine, ibuprofen, ethenzamide, sazapyrine, salicylamide, sodium salicylate, thiaramide hydrochloride, lactylphenetidine and the like.
鎮咳成分としては、例えば、アロクラミド塩酸塩、エプラジノン塩酸塩、カルベタペンタンクエン酸塩、クロぺラスチン塩酸塩、クロぺラスチンフェンジゾ酸塩、コデインリン酸塩、ジヒドロコデインリン酸塩、ジブナートナトリウム、ジメモルファンリン酸塩、デキストロメトルファン臭化水素酸塩、デキストロメトルファン・フェノールフタリン塩、チぺピジンクエン酸塩、チぺピジンヒベンズ酸塩等が挙げられる。
ノスカピン類としては、例えば、ノスカピン塩酸塩、ノスカピン等が挙げられる。
去痰成分としては、例えば、アンブロキソール塩酸塩、アンモニア・ウイキョウ精、エチルシステイン塩酸塩、塩化アンモニウム、カルボシステイン、グアイフェネシン、グアヤコールスルホン酸カリウム、クレゾールスルホン酸カリウム、ブロムヘキシン塩酸塩、メチルシステイン塩酸塩、l−メントール等が挙げられる。
Antitussive components include, for example, aloclamide hydrochloride, eprazinone hydrochloride, carbetapentane enoate, cloperastine hydrochloride, cloperastine phendizoate, codeine phosphate, dihydrocodeine phosphate, dibutate sodium , Dimemorphan phosphate, dextromethorphan hydrobromide, dextromethorphan / phenolphthaline salt, tipepidine citrate, tipipedin hibenzate and the like.
Examples of noscapine include noscapine hydrochloride and noscapine.
As the expectorant component, for example, ambroxol hydrochloride, ammonia fennel, ethylcysteine hydrochloride, ammonium chloride, carbocysteine, guaifenesin, potassium guaiacolsulfonate, potassium cresolsulfonate, bromhexine hydrochloride, methylcysteine hydrochloride, and l-menthol.
催眠鎮静成分としては、例えば、アリルイソプロピルアセチル尿素、ブロムワレリル尿素等が挙げられる。
ビタミン類としては、例えば、ビタミンB1、ビタミンB2、ビタミンB5、ビタミンB6、ビタミンB12、ビタミンC、ヘスぺリジン及びその誘導体並びにそれらの塩類等(例えば、チアミン、チアミン塩化物塩酸塩、チアミン硝化物、ジセチアミン塩酸塩、セトチアミン塩酸塩、フルスルチアミン、フルスルチアミン塩酸塩、オクトチアミン、シコチアミン、チアミンジスルフィド、ビスイブチアミン、ビスベンチアミン、プロスルチアミン、ベンフォチアミン、リボフラビン、リボフラビンリン酸エステル、リボフラビン酪酸エステル、リン酸リボフラビンナトリウム、パンテノール、パンテチン、パントテン酸カルシウム、パントテン酸ナトリウム、ピリドキシン塩酸塩、ピリドキサールリン酸エステル、シアノコバラミン、メコバラミン、アスコルビン酸、アスコルビン酸ナトリウム、アスコルビン酸カルシウム、ヘスぺリジン等)が挙げられる。
Examples of the hypnotic sedative component include allyl isopropyl acetylurea, bromvalerylurea and the like.
Examples of vitamins include vitamin B1, vitamin B2, vitamin B5, vitamin B6, vitamin B12, vitamin C, hesperidin and derivatives thereof, and salts thereof (for example, thiamine, thiamine chloride hydrochloride, thiamine nitrate) , Dicetiamine hydrochloride, sethiamine hydrochloride, fursultiamine, fursultiamine hydrochloride, octothiamine, chicotiamine, thiamine disulfide, bisbutiamine, bisbenchamine, prosultiamine, benfotiamine, riboflavin, riboflavin phosphate, Riboflavin butyrate, sodium riboflavin phosphate, panthenol, panthetin, calcium pantothenate, sodium pantothenate, pyridoxine hydrochloride, pyridoxal phosphate, cyanocobalamin, meco Lamin, ascorbic acid, sodium ascorbate, calcium ascorbate, Hesupe lysine, etc.).
胃粘膜保護成分としては、例えば、アミノ酢酸、アルジオキサ、ケイ酸マグネシウム、ゲファルナート、合成ケイ酸アルミニウム、合成ヒドロタルサイト、酸化マグネシウム、ジヒドロキシアルミニウム・アミノ酢酸塩(アルミニウムグリシネート)、水酸化アルミニウムゲル、水酸化アルミニウム・炭酸マグネシウム混合乾燥ゲル、水酸化アルミニウム・炭酸水素ナトリウム共沈生成物、水酸化アルミニウム・炭酸カルシウム・炭酸マグネシウム共沈生成物、水酸化マグネシウム・硫酸アルミニウムカリウム共沈生成物、スクラルファート、セトラキサート塩酸塩、ソファルコン、炭酸マグネシウム、テプレノン、銅クロロフィリンカリウム、銅クロロフィリンナトリウム、メタケイ酸アルミン酸マグネシウム、メチルメチオニンスルホニウムクロリド等が挙げられる。
キサンチン系成分としては、例えば、アミノフィリン、ジプロフィリン、テオフィリン、ブロキシフィリン等が挙げられる。
Examples of the gastric mucosa protective component include aminoacetic acid, aldioxa, magnesium silicate, gefarnate, synthetic aluminum silicate, synthetic hydrotalcite, magnesium oxide, dihydroxyaluminum aminoacetate (aluminum glycinate), aluminum hydroxide gel, Aluminum hydroxide / magnesium carbonate mixed dry gel, aluminum hydroxide / sodium bicarbonate coprecipitation product, aluminum hydroxide / calcium carbonate / magnesium carbonate coprecipitation product, magnesium hydroxide / potassium aluminum sulfate coprecipitation product, sucralfate, Cetraxate hydrochloride, sofalcone, magnesium carbonate, teprenone, copper chlorophyllin potassium, copper chlorophyllin sodium, magnesium metasilicate aluminate, methylmethionine sulfonate Mukurorido, and the like.
Examples of xanthine components include aminophylline, diprofylline, theophylline, broxifylline and the like.
生薬類としては、例えば、アカメガシワ(赤芽柏)、アセンヤク(阿仙薬)、インヨウカク(淫羊霍)、ウイキョウ(茴香)、ウコン(鬱金)、エンゴサク(延胡索)、エンメイソウ(延命草)、オウゴン(黄岑)、オウセイ(黄精)、オウバク(黄柏)、オウヒ(桜皮)、オウレン(黄連)、オンジ(遠志)、ガジュツ(我朮)、カノコソウ(鹿子草)、カミツレ、カロニン(か楼仁)、カンゾウ(甘草)、キキョウ(桔梗)、キョウニン(杏仁)、クコシ(枸杞子)、クコヨウ(枸杞葉)、ケイガイ(荊芥)、ケイヒ(桂皮)、ケツメイシ(決明子)、ゲンチアナ、ゲンノショウコ(現証拠)、コウブシ(香附子)、ゴオウ(牛黄)、ゴミシ(五味子)、サイシン(細辛)、サンショウ(山椒)、シオン(紫苑)、ジコッピ(地骨皮)、シャクヤク(芍薬)、ジャコウ(麝香)、シャジン(沙参)、シャゼンシ(車前子)、シャゼンソウ(車前草)、獣胆(ユウタン(熊胆)を含む)、ショウキョウ(生姜)、ジリュウ(地竜)、シンイ(辛夷)、セキサン(石蒜)、セネガ、センキュウ(川きゅう)、ゼンコ(前胡)、センブリ(千振)、ソウジュツ(蒼朮)、ソウハクヒ(桑白皮)、ソヨウ(蘇葉)、タイサン(大蒜)、チクセツニンジン(竹節人参)、チョウジ(丁子)、チンピ (陳皮)、トウキ(当帰)、トコン(吐根)、ナンテンジツ(南天実)、ニンジン(人参)、バイモ(貝母)、バクモンドウ(麦門冬)、ハッカ(薄荷)、ハンゲ(半夏)、バンコウカ(番紅花)、ハンピ(反鼻)、ビャクシ(白し)、ビャクジュツ(白朮)、ブクリョウ(茯苓)、ボタンピ(牡丹皮)、ボレイ(牡蠣)、ロクジョウ(鹿茸)等の生薬及びこれらの抽出物(エキス、チンキ、乾燥エキス等)等が挙げられる。
本発明の医薬組成物における生薬類の含有量は特に限定されないが、例えば、医薬組成物全質量に対して10〜80質量%含有するのが好ましく、30〜60質量%含有するのがより好ましい。
Herbal medicines include, for example, akamegashiwa (red buds), asenyaku (asenyaku), inyoukaku (horny lamb), fennel (yuka), turmeric (depressed gold), engosaku (yenkogyo), enmaiso (extended herb), ogon (yellow jade) ), Ousei (yellow spirit), Owaku (yellow twilight), Spruce (cherry bark), Auren (yellow ream), Onji (distant), Gajutsu (weather), valerian (deer grass), chamomile, caronin (karojin), Licorice, licorice, bellflowers, kokushi (coconut), cucumber (cucumber leaves), keigai (cocoon), keihi (cinnamon), ketsumeishi (actual child), gentian, gennoshouko (current evidence), Koubushi (Kosuke), Gooh (Gyuhuang), Goshi (Gomiko), Saishin (Spicy), Salamander (Sambu), Zion (Purple), Zykopi (Peel), Peonies (Glue), Ji Jakkou, Shajin, Shazenshi (car forerunner), Shazenso (car forerunner), Beast gall (including yutan (gum gal)), Shakyo (ginger), Giryu (land dragon), Xinyi ), Sexan (Ishizuchi), Senega, Senkyu (Ryukyu), Zenko (Mae-Hu), Senburi (Senshu), Sojutsu (蒼朮), Sohakuhi (Mulberry white skin), Soyo (Soba), Taisan (Oiso), Chixetsu Carrot (Takebushi Ginseng), Clove (Chiko), Chimp (Chan), Toki (Toki), Tokon (Nanten), Carrot (Ginseng), Baimo (Shell), Bacmond (Wheat) Gate winter), mint (light load), Hange (semi-summer), bankouka (banka), hampi (anti-nose), juniper (white bean), juniper (white moth), bukkuri (茯苓), button pi (peony skin), volley (Oysters), Rokujo (deer) etc. These extracts (extract, tincture, dry extract, etc.) and the like.
The content of the herbal medicine in the pharmaceutical composition of the present invention is not particularly limited, but for example, it is preferably 10 to 80% by mass, more preferably 30 to 60% by mass with respect to the total mass of the pharmaceutical composition. .
漢方処方としては、例えば、ケイシトウ(桂枝湯)、コウソサン(香蘇散)、サイコケイシトウ(柴胡桂枝湯)、ショウサイコトウ(小柴胡湯)、バクモンドウトウ(麦門冬湯)、ハンゲコウボクトウ(半夏厚朴湯)等が挙げられる。 Examples of Kampo prescriptions include Keishito (Katsura-yu), Kousosan (Kousosan), Psycho-keito (Shibako), Bakumondou (Bakumontoyu), Hange Examples include Kokubokuto (half-summer Koboku-yu).
本発明の医薬組成物は、下記試験例に示す通り、優れた鼻閉抑制作用を有することから、鼻炎症状の治療又は緩和に有効である。従って、本発明の医薬組成物は、鼻炎症状の治療又は緩和用組成物として、より具体的には、急性鼻炎、アレルギー性鼻炎若しくは副鼻腔炎に起因する症状(くしゃみ、鼻水、鼻づまり、なみだ目、のどの痛み、頭重などが挙げられ、鼻づまりが好ましい。)、又は風邪の諸症状(鼻水、鼻づまり、くしゃみなどが挙げられ、鼻づまりが好ましい。)の治療又は緩和用組成物として好適に利用でき、例えば、鼻炎用内服薬、かぜ薬(感冒薬)などとすることができる。 As shown in the following test examples, the pharmaceutical composition of the present invention has an excellent inhibitory effect on nasal congestion, and is therefore effective for treating or alleviating nasal inflammation. Therefore, the pharmaceutical composition of the present invention is a composition for treating or alleviating nasal inflammation, more specifically, symptoms caused by acute rhinitis, allergic rhinitis or sinusitis (sneezing, runny nose, stuffy nose, Suitable for treatment or alleviation of throat, sore throat, headache, etc., and nasal congestion is preferable), or various symptoms of cold (including runny nose, nasal congestion, sneezing, etc., preferably nasal congestion) For example, it can be used as an internal medicine for rhinitis, a cold medicine (cold medicine), and the like.
以下に実施例等を挙げて本発明を詳細に説明するが、本発明はこれら実施例等に何ら限定されるものではない。 Hereinafter, the present invention will be described in detail with reference to examples, but the present invention is not limited to these examples.
[試験例1]鼻閉抑制作用の評価
メチルエフェドリン及びその塩よりなる群から選ばれる1種以上とフェニレフリン及びその塩よりなる群から選ばれる1種以上との組み合わせによる鼻閉抑制作用を、以下に示す鼻炎モデルにおける、色素漏出抑制作用として評価した。
[Test Example 1] Evaluation of nasal obstruction inhibitory action The nasal obstruction inhibitory action by a combination of one or more selected from the group consisting of methylephedrine and its salt and one or more selected from the group consisting of phenylephrine and its salt is as follows: In the rhinitis model shown in FIG.
10週齢程度のSD系雄性ラットに被験薬物又は対照物質(0.5%メチルセルロース水溶液)を経口投与した。経口投与の3時間後に、ペントバルビタールを40mg/kg体重の用量で腹腔内投与することにより麻酔し、頚部を切開して気管カニューレ及び鼻腔洗浄用のポリエチレンチューブを挿入した。施術後、鼻腔に留置したポリエチレンチューブから生理食塩水を10mL注入して洗浄するとともに、エバンスブルー溶液を50mg/kg体重の用量で尾静脈投与した。
被験薬物又は対照物質の経口投与から4時間後に、鼻腔に留置したポリエチレンチューブから0.75mLの1mMブラジキニン溶液を注入して鼻粘膜浮腫(鼻閉)を惹起した。その5分後に、1mLの生理食塩水をポリエチレンチューブに注入し鼻腔を洗浄した後洗浄液を回収し、その洗浄液中の色素漏出量(μg/mL)を評価した。
そして、得られた色素漏出量から、以下の式に従い、鼻閉抑制率を算出した。
A test drug or a control substance (0.5% aqueous methylcellulose solution) was orally administered to SD male rats of about 10 weeks of age. Three hours after oral administration, pentobarbital was anesthetized by intraperitoneal administration at a dose of 40 mg / kg body weight, the neck was incised, and a tracheal cannula and a polyethylene tube for nasal irrigation were inserted. After the operation, 10 mL of physiological saline was injected from a polyethylene tube placed in the nasal cavity and washed, and the Evans blue solution was administered via the tail vein at a dose of 50 mg / kg body weight.
Four hours after oral administration of the test drug or control substance, 0.75 mL of 1 mM bradykinin solution was injected from a polyethylene tube placed in the nasal cavity to induce nasal mucosal edema (nasal obstruction). Five minutes later, 1 mL of physiological saline was injected into the polyethylene tube to wash the nasal cavity, and then the cleaning solution was collected, and the amount of dye leakage (μg / mL) in the cleaning solution was evaluated.
And the nasal closure suppression rate was computed from the obtained pigment | dye leakage amount according to the following formula | equation.
鼻閉抑制率(%)=(対照物質投与群の色素漏出量の平均値−各被験薬物投与群の色素漏出量の平均値)/対照物質投与群の色素漏出量の平均値×100 Nasal obstruction inhibition rate (%) = (average value of dye leakage amount in control substance administration group−average value of dye leakage amount in each test drug administration group) / average value of dye leakage amount in control substance administration group × 100
なお、色素漏出量は、鼻腔洗浄液の630nmにおける吸光度を測定することにより評価した。 The amount of dye leakage was evaluated by measuring the absorbance at 630 nm of the nasal cavity washing solution.
被験薬物は、それぞれ以下の群構成に従い投与した。
1:dl−メチルエフェドリン塩酸塩 単独投与群(以下、「ME単独」と表記する。)
dl−メチルエフェドリン塩酸塩を45mg/kg体重の用量で、0.5%メチルセルロース水溶液に溶解又は懸濁させて投与した。
2:フェニレフリン塩酸塩 単独投与群(以下、「PE単独」と表記する。)
フェニレフリン塩酸塩を18mg/kg体重の用量で、0.5%メチルセルロース水溶液に溶解又は懸濁させて投与した。
3:dl−メチルエフェドリン塩酸塩とフェニレフリン塩酸塩の併用投与群(以下、「ME+PE」と表記する。)
dl−メチルエフェドリン塩酸塩を45mg/kg体重の用量で、フェニレフリン塩酸塩を15mg/kg体重の用量で、それぞれ0.5%メチルセルロース水溶液に溶解又は懸濁させて投与した。
Each test drug was administered according to the following group composition.
1: dl-methylephedrine hydrochloride alone administration group (hereinafter referred to as “ME alone”)
dl-Methylephedrine hydrochloride was administered at a dose of 45 mg / kg body weight dissolved or suspended in 0.5% aqueous methylcellulose solution.
2: Phenylephrine hydrochloride alone administration group (hereinafter referred to as “PE alone”)
Phenylephrine hydrochloride was administered at a dose of 18 mg / kg body weight dissolved or suspended in a 0.5% aqueous methylcellulose solution.
3: A combined administration group of dl-methylephedrine hydrochloride and phenylephrine hydrochloride (hereinafter referred to as “ME + PE”)
dl-Methylephedrine hydrochloride was administered at a dose of 45 mg / kg body weight, and phenylephrine hydrochloride was administered at a dose of 15 mg / kg body weight, each dissolved or suspended in a 0.5% aqueous methylcellulose solution.
なお、それぞれ各群につき、4〜5匹のラットを使用した。
結果を表1に示す。なお、色素漏出量は平均値±標準誤差で表示した。
In addition, 4-5 rats were used for each group.
The results are shown in Table 1. The amount of dye leakage was expressed as an average value ± standard error.
表1に示す試験結果より、dl−メチルエフェドリン塩酸塩とフェニレフリン塩酸塩の組み合わせ(ME+PE)は、両成分それぞれ単独投与による作用の総和以上の優れた鼻閉抑制作用を有することが明らかとなった。
また、フェニレフリン塩酸塩 18mg/kg体重の単独投与では殆ど鼻閉が抑制されなかった(PE単独:鼻閉抑制率 0%)にも拘わらず、これよりも少量(15mg/kg体重)にてdl−メチルエフェドリン塩酸塩と組み合わせて投与することで、dl−メチルエフェドリン塩酸塩のみの単独投与と比較して2倍近い鼻閉抑制作用が奏されることが明らかとなった(ME単独:鼻閉抑制率 34%、PE単独:鼻閉抑制率 0%、ME+PE:鼻閉抑制率 56%)。
From the test results shown in Table 1, it became clear that the combination of dl-methylephedrine hydrochloride and phenylephrine hydrochloride (ME + PE) has an excellent nasal obstruction inhibitory effect that is equal to or greater than the sum of the effects of each component alone. .
In addition, phenylephrine hydrochloride 18 mg / kg body weight alone did not substantially suppress nasal obstruction (PE alone: nasal obstruction inhibition rate 0%), but dl in a smaller amount (15 mg / kg body weight). -It was clarified that administration in combination with methylephedrine hydrochloride exerted a nasal obstruction suppression effect nearly twice that of single administration of dl-methylephedrine hydrochloride alone (ME alone: nasal obstruction) Suppression rate 34%, PE alone: nasal congestion suppression rate 0%, ME + PE: nasal congestion suppression rate 56%).
以上の試験結果から、メチルエフェドリン及びその塩から選ばれる1種以上と、フェニレフリン及びその塩から選ばれる1種以上との組み合わせは、格別に優れた鼻閉抑制作用を有することが明らかとなった。 From the above test results, it became clear that the combination of one or more selected from methylephedrine and its salt and one or more selected from phenylephrine and its salt has a particularly excellent nasal obstruction inhibitory action. .
[試験例2]鼻閉改善に関する評価
特許文献1の試験例を参考に、1日服用量としてdl−メチルエフェドリン塩酸塩を45mg、塩酸フェニレフリン15mgを含有する製剤を製造し、鼻閉を訴える成人男性(47歳)に、同意のうえ2日間、1日3回、食後30分以内に服用してもらった。服薬後、鼻閉の症状に関しヒアリングしたところ、服薬30分後、1時間後、3時間後のいずれにおいても症状が殆ど残っていない旨の回答が得られた。
[Test Example 2] Evaluation on improvement of nasal congestion An adult complaining of nasal congestion by producing a preparation containing 45 mg of dl-methylephedrine hydrochloride and 15 mg of phenylephrine hydrochloride as a daily dose with reference to the test example of Patent Document 1 A man (47 years old) took the medicine for 3 days a day for 3 days with consent and within 30 minutes after eating. After taking the drug, interviews were conducted regarding the symptoms of nasal congestion. As a result, there was a reply that almost no symptoms remained at 30 minutes, 1 hour, and 3 hours after taking the medicine.
[試験例3]鼻閉改善に関する評価 その2
特許文献1の試験例を参考に、1日服用量としてdl−メチルエフェドリン塩酸塩45mg、塩酸フェニレフリン15mgに加えて、さらにd‐クロルフェニラミンマレイン酸塩6mgを含有する製剤を製造し、試験例2と同じ成人男性に、同意のうえ日を違えて2日間、1日3回、食後30分以内に服用してもらった。服薬後、鼻閉の症状に関しヒアリングしたところ、服薬30分後、1時間後、3時間後のいずれにおいても症状が残っていない旨の回答が得られた。また、試験例2の製剤と比較した使用感に関しヒアリングしたところ、試験例3の製剤の方が特に持続的に鼻閉を抑制する旨の回答が得られた。
[Test Example 3] Evaluation of improvement in nasal congestion No. 2
In addition to 45 mg of dl-methylephedrine hydrochloride and 15 mg of phenylephrine hydrochloride as a daily dose with reference to the test example of Patent Document 1, a preparation containing 6 mg of d-chlorpheniramine maleate was further produced. The same adult male as in No. 2 had taken the medicine on a different date, taking 3 days a day for 3 days within 30 minutes after meals. After taking the drug, interviews were conducted regarding the symptoms of nasal congestion. As a result, an answer was obtained that no symptoms remained after 30 minutes, 1 hour, and 3 hours after taking the medicine. Moreover, when hearing was conducted regarding the usability compared with the preparation of Test Example 2, an answer was obtained that the preparation of Test Example 3 suppressed nasal congestion more continuously.
[試験例4]鼻閉改善に関する評価 その3
特許文献1の試験例を参考に、1日服用量としてdl−メチルエフェドリン塩酸塩45mg、塩酸フェニレフリン15mgに加えて、さらにメキタジン4mgを含有する製剤を製造し、試験例2と同じ成人男性に、同意のうえ日を違えて2日間、1日3回、食後30分以内に服用してもらった。服薬後、鼻閉の症状に関しヒアリングしたところ、服薬30分後、1時間後、3時間後のいずれにおいても症状が残っていない旨の回答が得られた。また、試験例2の製剤と比較した使用感に関しヒアリングしたところ、試験例4の製剤の方が特に持続的に鼻閉を抑制する旨の回答が得られた。
[Test Example 4] Evaluation on improvement of nasal congestion No. 3
In reference to the test example of Patent Document 1, in addition to 45 mg of dl-methylephedrine hydrochloride and 15 mg of phenylephrine hydrochloride as a daily dose, a preparation containing 4 mg of mequitazine was further produced. After consenting, they were taken on different days for 2 days, 3 times a day, within 30 minutes after meals. After taking the drug, interviews were conducted regarding the symptoms of nasal congestion. As a result, an answer was obtained that no symptoms remained after 30 minutes, 1 hour, and 3 hours after taking the medicine. Further, as a result of hearing about the feeling of use compared with the preparation of Test Example 2, an answer was obtained that the preparation of Test Example 4 particularly continually suppressed nasal congestion.
[製造例1]
1日量(3カプセル)中に以下の成分・分量を含有する軟カプセル剤を常法により製造できる。
d−マレイン酸クロルフェニラミン 6mg
塩酸dl−メチルエフェドリン 60mg
塩酸フェニレフリン 15mg
グリチルリチン酸二カリウム 60mg
ベラドンナ総アルカロイド 0.4mg
無水カフェイン 90mg
添加物:ポリソルベート80、グリセリン脂肪酸エステル、サラシミツロウ、中鎖脂肪酸トリグリセリド、ゼラチン、グリセリン、酸化チタン。
[Production Example 1]
A soft capsule containing the following components and amounts in a daily dose (3 capsules) can be produced by a conventional method.
d-Chlorpheniramine maleate 6mg
Dl-Methylephedrine hydrochloride 60mg
Phenylephrine hydrochloride 15mg
Dipotassium glycyrrhizinate 60mg
Belladonna Total Alkaloid 0.4mg
Anhydrous caffeine 90mg
Additives: Polysorbate 80, glycerin fatty acid ester, honey beeswax, medium chain fatty acid triglyceride, gelatin, glycerin, titanium oxide.
[製造例2]
1日量(3カプセル)中に以下の成分・分量を含有する軟カプセル剤を常法により製造できる。
メキタジン 4mg
塩酸プソイドエフェドリン 75mg
dl−メチルエフェドリン塩酸塩 60mg
塩酸フェニレフリン 10mg
ベラドンナ総アルカロイド 0.4mg
無水カフェイン 90mg
添加物:ポリソルベート80、グリセリン脂肪酸エステル、サラシミツロウ、中鎖脂肪酸トリグリセリド、ゼラチン、濃グリセリン、酸化チタン。
[Production Example 2]
A soft capsule containing the following components and amounts in a daily dose (3 capsules) can be produced by a conventional method.
Mequitazine 4mg
Pseudoephedrine hydrochloride 75mg
dl-Methylephedrine hydrochloride 60mg
Phenylephrine hydrochloride 10mg
Belladonna Total Alkaloid 0.4mg
Anhydrous caffeine 90mg
Additives: Polysorbate 80, glycerin fatty acid ester, honey beeswax, medium chain fatty acid triglyceride, gelatin, concentrated glycerin, titanium oxide.
[製造例3]
1日量(3枚)中に以下の成分・分量を含有する経口フィルム剤を常法により製造できる。
d−クロルフェニラミンマレイン酸塩 6mg
ベラドンナ総アルカロイド 0.6mg
フェニレフリン塩酸塩 15mg
dl−メチルエフェドリン塩酸塩 22mg
添加物:ヒプロメロース、還元麦芽糖水アメ、酸化チタン、l−メントール、ヒドロキシプロピルセルロース、サッカリンNa、エリスリトール、亜硫酸水素Na、香料、青色一号アルミニウムレーキ。
[Production Example 3]
An oral film containing the following components and amounts in a daily dose (3 sheets) can be produced by a conventional method.
d-Chlorpheniramine maleate 6mg
Belladonna Total Alkaloid 0.6mg
Phenylephrine hydrochloride 15mg
dl-Methylephedrine hydrochloride 22mg
Additives: hypromellose, reduced maltose water candy, titanium oxide, l-menthol, hydroxypropylcellulose, saccharin Na, erythritol, sodium hydrogen sulfite, flavor, blue No. 1 aluminum lake.
[製造例4]
1日量(4カプセル)中に以下の成分・分量を含有する軟カプセル剤を常法により製造できる。
クロルフェニラミンマレイン酸塩 8mg
ベラドンナ総アルカロイド 0.4mg
フェニレフリン塩酸塩 6mg
dl−メチルエフェドリン塩酸塩 110mg
リゾチーム塩酸塩 60mg(力価)
無水カフェイン 100mg
添加物:トウモロコシデンプン、乳糖、セルロース、ヒドロキシプロピルセルロース、カルメロースカルシウム、エチルセルロース、グリセリン脂肪酸エステル、タルク、部分アルファー化デンプン、ゼラチン、青色1号、ラウリル硫酸ナトリウム。
[Production Example 4]
A soft capsule containing the following components and amounts in a daily dose (4 capsules) can be produced by a conventional method.
Chlorpheniramine maleate 8mg
Belladonna Total Alkaloid 0.4mg
Phenylephrine hydrochloride 6mg
dl-Methylephedrine hydrochloride 110 mg
Lysozyme hydrochloride 60mg (titer)
Anhydrous caffeine 100mg
Additives: corn starch, lactose, cellulose, hydroxypropyl cellulose, carmellose calcium, ethyl cellulose, glycerin fatty acid ester, talc, partially pregelatinized starch, gelatin, blue No. 1, sodium lauryl sulfate.
[製造例5]
1日量(2カプセル)中に以下の成分・分量を含有する軟カプセル剤を常法により製造できる。
マレイン酸カルビノキサミン 6mg
ベラドンナ総アルカロイド 0.2mg
フェニレフリン塩酸塩 30mg
dl−メチルエフェドリン塩酸塩 22mg
リゾチーム塩酸塩 15mg(力価)
無水カフェイン 50mg
添加物:メタケイ酸アルミン酸マグネシウム、白糖、トウモロコシデンプン、ヒドロキシプロピルセルロース、ステアリン酸マグネシウム、セルロース、タルク、アンモニオアルキルメタクリレートコポリマー、ステアリルアルコール、ソルビタン脂肪酸エステル、黄色5号、ゼラチン、ラウリル硫酸ナトリウム。
[Production Example 5]
A soft capsule containing the following components and amounts in a daily dose (2 capsules) can be produced by a conventional method.
Carbinoxamine maleate 6mg
Belladonna Total Alkaloid 0.2mg
Phenylephrine hydrochloride 30mg
dl-Methylephedrine hydrochloride 22mg
Lysozyme hydrochloride 15mg (titer)
Anhydrous caffeine 50mg
Additives: Magnesium aluminate metasilicate, sucrose, corn starch, hydroxypropyl cellulose, magnesium stearate, cellulose, talc, ammonioalkyl methacrylate copolymer, stearyl alcohol, sorbitan fatty acid ester, yellow No. 5, gelatin, sodium lauryl sulfate.
[製造例6]
1日量(3カプセル)中に以下の成分・分量を含有する軟カプセル剤を常法により製造できる。
クレマスチンフマル酸塩 1.34mg
塩酸プソイドエフェドリン 75mg
dl−メチルエフェドリン塩酸塩 60mg
塩酸フェニレフリン 10mg
ベラドンナ総アルカロイド 0.4mg
無水カフェイン 90mg
添加物:ポリソルベート80、グリセリン脂肪酸エステル、サラシミツロウ、中鎖脂肪酸トリグリセリド、ゼラチン、濃グリセリン、酸化チタン。
[Production Example 6]
A soft capsule containing the following components and amounts in a daily dose (3 capsules) can be produced by a conventional method.
Cremastine fumarate 1.34mg
Pseudoephedrine hydrochloride 75mg
dl-Methylephedrine hydrochloride 60mg
Phenylephrine hydrochloride 10mg
Belladonna Total Alkaloid 0.4mg
Anhydrous caffeine 90mg
Additives: Polysorbate 80, glycerin fatty acid ester, honey beeswax, medium chain fatty acid triglyceride, gelatin, concentrated glycerin, titanium oxide.
本発明によれば、優れた薬理作用を有する医薬組成物を提供することができ、医薬品産業、医薬部外品産業等において好適に利用できる。 ADVANTAGE OF THE INVENTION According to this invention, the pharmaceutical composition which has the outstanding pharmacological action can be provided, and it can utilize suitably in pharmaceutical industry, a quasi-drug industry, etc.
Claims (6)
(A)メチルエフェドリン及びその塩よりなる群から選ばれる1種以上;
(B)フェニレフリン及びその塩よりなる群から選ばれる1種以上;
を含有する医薬組成物。 The following components (A) and (B):
(A) one or more selected from the group consisting of methylephedrine and salts thereof;
(B) one or more selected from the group consisting of phenylephrine and salts thereof;
A pharmaceutical composition comprising
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015127296A JP6616968B2 (en) | 2014-06-25 | 2015-06-25 | Pharmaceutical composition |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014130333 | 2014-06-25 | ||
JP2014130333 | 2014-06-25 | ||
JP2015127296A JP6616968B2 (en) | 2014-06-25 | 2015-06-25 | Pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016027022A true JP2016027022A (en) | 2016-02-18 |
JP6616968B2 JP6616968B2 (en) | 2019-12-04 |
Family
ID=55352600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015127296A Active JP6616968B2 (en) | 2014-06-25 | 2015-06-25 | Pharmaceutical composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6616968B2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004269517A (en) * | 2003-02-19 | 2004-09-30 | Rohto Pharmaceut Co Ltd | Medicinal composition |
-
2015
- 2015-06-25 JP JP2015127296A patent/JP6616968B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004269517A (en) * | 2003-02-19 | 2004-09-30 | Rohto Pharmaceut Co Ltd | Medicinal composition |
Non-Patent Citations (1)
Title |
---|
小児科診療, vol. Vol.61, No.Suppl, JPN6019007140, 1998, pages 1 - 2 * |
Also Published As
Publication number | Publication date |
---|---|
JP6616968B2 (en) | 2019-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6425767B2 (en) | Pharmaceutical composition containing loxoprofen <弐> | |
JP2019019132A (en) | Stable pharmaceutical composition | |
JP2018135372A (en) | Pharmaceutical composition <3> containing loxoprofen or salt thereof | |
JP5952944B2 (en) | Loxoprofen or a pharmaceutical composition containing a salt thereof II | |
JP6616968B2 (en) | Pharmaceutical composition | |
JP2017132819A (en) | Pharmaceutical composition containing loxoprofen or salt thereof | |
JP5624367B2 (en) | Loxoprofen-containing pharmaceutical preparation | |
JP5993498B2 (en) | Pharmaceutical composition containing loxoprofen or a salt thereof | |
JP2008115168A (en) | Anti-adenovirus agent | |
JP2013049729A (en) | Pharmaceutical composition | |
JP6010538B2 (en) | Stable pharmaceutical composition | |
JP2016169235A (en) | Loxoprofen-containing pharmaceutical composition | |
JP3987501B2 (en) | Pharmaceutical composition | |
JP6073231B2 (en) | Stable pharmaceutical composition | |
JP2014159377A (en) | Sublimation inhibition method for sublimable medicine | |
JP5794807B2 (en) | Pharmaceutical composition containing loxoprofen and clemastine | |
WO2013047869A1 (en) | Pharmaceutical composition containing loxoprofen or salt thereof | |
JP2018076306A (en) | Cold remedy | |
JP5898964B2 (en) | Pharmaceutical composition containing loxoprofen or a salt thereof | |
JP2019127488A (en) | Pharmaceutical compositions comprising olopatadine | |
JP2013133299A (en) | Pharmaceutical composition including loxoprofen | |
JP2007039473A (en) | Medicinal composition | |
JP2006036662A (en) | Pharmaceutical composition containing pseudoephedrine and oxatomide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190305 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190417 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190626 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191111 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6616968 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |